Peter Steiner

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

FMH Swiss Medical Association operates an association for doctors and medical practitioners. The private company is based in Bern, Switzerland and has subsidiaries in Switzerland.

FiveT Capital AG (FiveT Capital) is an independent Swiss financial advisory firm which was founded by Johannes Minho Roth in 2006 which specializes in absolute return investment strategies. Formerly known as FiveT Capital Management AG, the firm aims to exploit opportunities in the European stock market, especially in Germany, by combining fundamental research and trading and execution. Based in Zurich, FiveT Capital manages the Cayman Islands-domiciled FiveMore Fund Ltd., backed primarily by high net-worth clients, funds of hedge funds and institutional investors. The firm operates their own trading and execution desk, allowing them to engage in proprietary trading and exploit market inefficiencies.

Part of Mallinckrodt Plc, Sucampo Acquisitions GmbH is a Swiss company that provides investment services. The company is based in Zug, Switzerland.

Numab Innovation AG develops multi-specific bio-therapeutics for chronic inflammation and cancer. The private company is based in Wädenswil, Switzerland.

Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland.

Part of Mallinckrodt Plc, Sucampo GmbH is a Swiss company that manufactures and distributes pharmaceuticals and health care products. The company is based in Zug, Switzerland. The company was founded by Ryuji Ueno, Sachiko Kuno. Sucampo was acquired by Sucampo Pharmaceuticals LLC, part of Mallinckrodt Plc from February 14, 2018 on December 29, 2010 for $120 million.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

The DePuy Synthes Inc. provides orthopaedic and neuro products and services in the areas of joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools and biomaterials. The company was founded in 1895 and is headquartered in Warsaw, IN.

Acino Pharma AG engages in the development, production, and distribution of chemical and pharmaceutical products. It also acquires, manages, and sells participating interests in firms, real estate, and intellectual property rights. The company was founded in 1961 and is headquartered in Liesberg, Switzerland.

Fivet Capital AG (Private Banking) (Fivet Capital-PB) is the private banking division subsidiary of Fivet Capital AG, a hedge fund manager headquartered in Zurich, Switzerland. The firm was founded in 2006 and formerly known as FiveT Capital Wealth Management. Fivet Capital-PB provides wealth management and advisory services to high-net worth individuals, family offices and institutional investors.

Viramed Biotech AG is a German company that specializes in infection serology and autoimmune diagnostics for human medicine. The private company was founded in 1983 and is based in Planegg, Germany. The company offers a range of products, including the Virachip® immunoblots, which can detect antibodies for various infections such as CMV, EBV, and SARS-CoV-2. The company also provides automation solutions for processing Virachip® tests, as well as IFt immunofluorescence tests and ELISA assays for parasite diagnostics.

InSphero AG supplies organotypic 3D microtissues for efficiency testing and toxicology in drug development. It offers 3D insight Islet, 3D InSight Tumor, Gravity TRAP ULA Plates, Cytotoxicity Assay Kit, 3D InSight in Vitro Toxixology services, imaging and automation. he company was founded by Jan Lichtenberg, Jens M. Kelm, Simon P. Hoerstrup and Wolfgang Moritz on March 26, 2009 and is headquartered in Schlieren, Switzerland.

Kinled Holding Ltd. provides investment services. The firm focuses on finance, real estate, medical and technology sectors for its private equity investments. Kinled Holding was founded in 1980 and is headquartered in Hong Kong.

The Swiss Private Equity & Corporate Finance Association (SECA) is an organization that represents the private equity, venture capital, and corporate finance industries in Switzerland. The non-profit company is based in Switzerland. SECA aims to promote and support these activities within the country.

FiveT Fintech AG (FiveT Fintech) is a venture capital firm founded in 2018 by Francisco Fernandez Griñon and Alexander Christen. The firm is headquartered in Zurich, Switzerland.

FiveT Capital Holding AG provides investment related services. The private company is based in Pfäffikon, Switzerland. The Swiss company was founded by Johannes Minho Roth. Johannes Minho Roth has been the CEO since incorporation.

Synthes, Inc. engages in the development, production, and marketing of instruments, implants, as well as biomaterials for surgical fixation, correction, and regeneration of the human skeleton and its soft tissues. The company was founded in 1999 and is headquartered in Solothurn, Switzerland.

Humabs BioMed SA is an antibody therapeutics biotechnology company. It develops human monoclonal antibody platforms for treatment of infectious and inflammatory diseases. The company was founded by Prof. Antonio Lanzavecchia on October 24, 2011 and is headquartered in Bellinzona, Switzerland.

The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year.

SuppreMol GmbH engages in the development and use of active substances for the therapy of autoimmune diseases and allergies, as well as the research on and development of medicinal products. It also produces medicines through licensed manufacturers. The products are supplied via pharmaceutical wholesale. The company was founded by Robert Huber, Uwe Jacob, and Peter Sondermann in 2002 and is headquartered in Berlin, Germany.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.